Red blood cell transfusions can be lifesaving for people with myelodysplastic syndromes, especially when anemia turns a walk to the mailbox into an Olympic event. However, repeated transfusions bring an unwanted passenger: iron. Because the human body has no efficient way to eliminate large amounts of excess iron, it can gradually accumulate in the liver, heart, endocrine organs, and other tissues.
This complication is known as transfusional iron overload. It is most relevant to people with lower-risk MDS who receive regular red blood cell transfusions over months or years. Iron overload does not mean transfusions were a mistake. It means their long-term effects need to be monitored and managed as part of the overall MDS treatment plan.
Doctors generally evaluate more than one number before recommending treatment. Transfusion history, serum ferritin trends, liver and kidney function, MDS risk category, expected survival, other medical conditions, and possible stem cell transplantation may all influence the decision.
What Is Iron Overload in MDS?
Myelodysplastic syndromes are a group of bone marrow cancers in which developing blood cells do not mature normally. The marrow may produce too few functional red blood cells, white blood cells, or platelets. Anemia is particularly common and may cause fatigue, weakness, shortness of breath, dizziness, headaches, and reduced exercise tolerance.
Red blood cell transfusions can quickly raise hemoglobin and relieve anemia symptoms. Unfortunately, every unit also delivers a substantial dose of iron. A typical unit of packed red blood cells contains approximately 200 to 250 milligrams of iron. After 20 units, a person may have received roughly 4,000 to 5,000 milligrams of additional iron.
That would be less concerning if the body had an iron disposal chute. It does not. Only small amounts are normally lost through bleeding, shedding of skin cells, and the digestive tract. When transfusions repeatedly add iron faster than the body can safely store it, excess iron begins circulating and accumulating in tissues.
Transfusions are not the only contributor
In some forms of MDS, ineffective red blood cell production may disrupt the hormone signals controlling iron absorption and storage. This can increase iron availability even before a very large transfusion burden has accumulated. MDS with ring sideroblasts, for example, involves abnormal iron deposits within developing red blood cells.
Still, repeated transfusion is usually the main driver of clinically important iron overload in MDS. The risk rises with the total number of red blood cell units received, the frequency of transfusion, and the length of time a person remains transfusion-dependent.
Why Excess Iron Can Become Harmful
Iron is essential for making hemoglobin and transporting oxygen. In excess, however, loosely bound iron can participate in chemical reactions that generate reactive oxygen species. These unstable molecules may damage cell membranes, proteins, mitochondria, and DNA. Think of iron as a useful kitchen knife: indispensable in the right place, troublesome when dozens are rolling loose in a drawer.
The liver is usually the primary storage site, so liver iron concentration often rises before serious cardiac iron accumulation occurs. Over time, excessive tissue iron may contribute to:
- Liver inflammation, fibrosis, or impaired liver function
- Cardiac dysfunction, abnormal heart rhythms, or heart failure
- Problems involving blood sugar regulation and endocrine organs
- Greater oxidative stress within the bone marrow environment
- Potentially poorer outcomes before or after stem cell transplantation
Importantly, most evidence connecting iron overload with complications in MDS comes from observational studies. People requiring many transfusions may already have more severe anemia or other health problems, making cause and effect difficult to separate. Iron overload is therefore treated as an important modifiable risknot as the explanation for every symptom, laboratory abnormality, or bad hair day.
Who Has the Highest Risk?
Iron overload deserves particular attention in patients who have lower-risk MDS and are expected to need ongoing transfusion support. Because these patients may live for years with chronic anemia, iron has more time to accumulate and affect organ health.
Risk factors commonly considered include:
- Receiving approximately 20 or more units of packed red blood cells
- Regular transfusions, such as one or more units per month
- A serum ferritin level persistently above approximately 1,000 micrograms per liter
- A continuing need for transfusions despite MDS-directed treatment
- Evidence of increased liver iron on magnetic resonance imaging
- Longer expected survival with lower-risk disease
- Plans for allogeneic stem cell transplantation
These are practical indicators, not an automatic treatment formula. A robust 67-year-old with lower-risk MDS, normal kidney function, and years of expected transfusion support presents a different situation from a frail 87-year-old with advanced disease, severe kidney impairment, and multiple competing health risks.
The current U.S. prescribing information for deferasirox states that treatment for transfusional iron overload should be considered when there is evidence of chronic iron loading, including a substantial transfusion history and serum ferritin consistently above 1,000 micrograms per liter. However, prescribing information also identifies situations in which the drug should not be used, including high-risk MDS and certain renal or platelet abnormalities.
How Iron Overload Is Diagnosed and Monitored
There is no single perfect test for iron overload in MDS. Doctors usually combine transfusion records, laboratory trends, imaging, organ function, and clinical context.
1. Transfusion history
The cumulative number of red blood cell units is one of the most practical measures. Patients and caregivers can help by keeping a transfusion log that includes dates and the number of units received. Hospital records may not always combine transfusions given at different facilities, so a personal record can prevent important history from disappearing into the electronic medical record wilderness.
2. Serum ferritin
Ferritin is the most widely used blood marker for stored iron. A steadily rising ferritin level in someone receiving repeated transfusions can support a diagnosis of iron overload. Many treatment discussions begin when ferritin remains above approximately 1,000 micrograms per liter.
Ferritin is helpful, but it is not clairvoyant. Infection, inflammation, liver injury, metabolic conditions, and active cancer can also increase it. One isolated high result should therefore be interpreted cautiously. The trend over several measurements is generally more informative than a single dramatic number.
3. Transferrin saturation
Transferrin saturation estimates how much of the blood’s iron-transport protein is carrying iron. A high value may suggest that storage and transport systems are becoming saturated. It can support the overall assessment, but it does not replace ferritin trends, imaging, or transfusion history.
4. Liver iron measurement by MRI
Specialized MRI techniques can estimate liver iron concentration without a biopsy. MRI is particularly useful when ferritin results are difficult to interpret, when the iron burden appears substantial, or when an accurate baseline could change the treatment plan.
Cardiac T2-star MRI may be considered when there is concern about heart iron or significant long-standing overload. Cardiac iron accumulation appears less common in MDS than liver iron accumulation, but it can be clinically important when present. MRI-based liver iron measurement is now widely accepted as a noninvasive method for assessing tissue iron.
5. Organ-function testing
Monitoring may include liver enzymes, bilirubin, serum creatinine, estimated glomerular filtration rate, urine protein, blood glucose, and cardiac evaluation when appropriate. These tests help detect complications and determine whether chelation can be used safely.
| Assessment | What It Shows | Important Limitation |
|---|---|---|
| Transfusion count | Approximate amount of iron introduced | Does not directly measure tissue iron |
| Serum ferritin | Trend in stored iron burden | May rise during inflammation or liver injury |
| Transferrin saturation | Degree of circulating iron saturation | Can vary and is not sufficient alone |
| Liver MRI | Estimated liver iron concentration | Cost and availability vary |
| Cardiac T2-star MRI | Possible heart iron deposition | Usually reserved for selected patients |
Can Iron Overload Cause Noticeable Symptoms?
Early transfusional iron overload often causes no distinct symptoms. Fatigue, weakness, shortness of breath, and reduced stamina are more likely to come from MDS-related anemia than from iron accumulation itself. That overlap is one reason routine monitoring matters.
Advanced organ involvement may produce symptoms such as abdominal discomfort, liver enlargement, swelling, irregular heartbeat, worsening shortness of breath, unusual changes in blood sugar, or signs of liver dysfunction. These symptoms are not specific to iron overload and require medical evaluation rather than a do-it-yourself diagnosis powered by an alarming search result.
Treating Iron Overload in MDS
Management has two broad goals: reduce the amount of new iron entering the body and remove some of the iron already accumulated. The treatment plan must be individualized because chelation adds medication burden and can cause serious adverse effects.
Reduce transfusion dependence when possible
Treatments that improve red blood cell production may reduce the number of transfusions and slow further iron loading. Depending on the MDS subtype, risk category, genetic findings, erythropoietin level, and previous therapy, these may include:
- Erythropoiesis-stimulating agents
- Luspatercept for eligible lower-risk MDS
- Lenalidomide, particularly for qualifying MDS with deletion 5q
- Hypomethylating agents in selected patients
- Other MDS-directed therapies or clinical trials
These medications are not substitutes for chelation when significant iron overload already exists. Their value is that fewer transfusions can mean less new iron arriving each month.
Iron chelation therapy
Chelators are prescription medications that bind iron so it can be removed through urine or stool. They are usually considered for carefully selected patients with transfusion-dependent, lower-risk MDS who have a meaningful expected survival and adequate organ function.
Deferasirox
Deferasirox is an oral chelator commonly used for transfusional iron overload. Its convenience is a major advantage over prolonged infusions, but “oral” does not mean casual. The dose may need adjustment according to ferritin trends, transfusion intensity, kidney function, liver tests, tolerance, and the specific formulation.
Deferasirox carries boxed warnings for acute kidney injury, hepatic failure, and gastrointestinal hemorrhage. Patients may also experience diarrhea, nausea, abdominal discomfort, rash, changes in creatinine, or protein in the urine. Older adults, people with multiple medical conditions, and those with low platelet counts may face greater risks.
Kidney and liver tests are required before and during therapy. Patients should urgently report reduced urination, jaundice, severe abdominal pain, vomiting blood, or black or bloody stools.
Deferoxamine
Deferoxamine is an established injectable chelator indicated for transfusional iron overload in chronic anemia. It may be given through a slow subcutaneous infusion, often over several hours. It can effectively remove iron, but the equipment, infusion schedule, and injection-site discomfort may make long-term adherence difficult.
Deferoxamine remains useful when oral therapy is inappropriate or poorly tolerated. Monitoring may include kidney function, hearing, vision, growth in younger patients, and infection risk, depending on the treatment circumstances.
What about deferiprone?
Deferiprone is another oral iron chelator, but its use in MDS requires particular caution. Product labeling and formulation-specific indications vary, and the drug carries a serious risk of neutropenia and agranulocytosis. That is an especially important concern in MDS, where white blood cell production may already be impaired.
Some U.S. prescribing information states that safety and effectiveness have not been established for transfusional iron overload in MDS. It should not be treated as an interchangeable over-the-counter cousin of deferasirox.
Why phlebotomy is usually unsuitable
Therapeutic phlebotomy removes iron by removing blood and is a standard treatment for hereditary hemochromatosis. It is generally unsuitable for transfusion-dependent MDS because the patient is already anemic and needs red blood cells rather than another person cheerfully taking them away.
Phlebotomy may occasionally become possible after successful treatment or stem cell transplantation restores adequate blood counts, but that is a specialized decision.
Does Diet Fix Transfusional Iron Overload?
Diet alone cannot remove the thousands of milligrams of iron delivered by repeated transfusions. A patient should not adopt an extremely restrictive “no-iron” diet without professional guidance, particularly when weight loss, poor appetite, or malnutrition is already a concern.
Practical steps may include avoiding iron supplements and iron-containing multivitamins unless a clinician has confirmed a separate need. Patients should also tell their hematology team about vitamin C supplements, herbal products, and fortified nutrition drinks. Ordinary balanced meals are rarely the main problem; bags of transfused red blood cells contain vastly more iron than Tuesday’s hamburger.
What Research Says About Chelation Outcomes
The TELESTO trial was a randomized, placebo-controlled study of deferasirox in adults with low- or intermediate-1-risk MDS and transfusional iron overload. Participants had received 15 to 75 units of packed red blood cells and had ferritin above 1,000 nanograms per milliliter.
Deferasirox prolonged median event-free survival compared with placebo. The composite endpoint included cardiac and liver events, progression to acute myeloid leukemia, and death. However, the trial did not demonstrate a statistically significant improvement in overall survival, and its interpretation was complicated by early closure, treatment discontinuation, and crossover to chelation.
Observational registries have also associated iron chelation with longer survival and, in some patients, improved blood counts or reduced transfusion requirements. These studies cannot completely eliminate selection bias: healthier patients with better kidney function and longer expected survival are more likely to receive chelation in the first place.
The most balanced conclusion is that chelation can lower iron burden and may improve clinically meaningful outcomes in selected lower-risk patients, but it is not automatically appropriate for every person with elevated ferritin.
Questions to Ask the Hematology Team
- How many red blood cell units have I received in total?
- Is my ferritin rising consistently, or could inflammation be affecting it?
- Would a liver iron MRI change my treatment plan?
- Am I likely to continue receiving regular transfusions?
- How does my MDS risk category affect the value of chelation?
- Are my kidney function, liver function, and platelet count suitable for treatment?
- Could an MDS-directed therapy reduce my transfusion needs?
- Which side effects should prompt an urgent call?
- How often will laboratory testing be required?
- Would iron overload affect a future stem cell transplant?
Conclusion
Iron overload in myelodysplastic syndromes is a long-term consequence of a treatment that many patients genuinely need. Red blood cell transfusions relieve anemia and can dramatically improve daily function, but each unit adds iron that the body cannot easily remove.
The best strategy is not to fear transfusions or chase one ferritin result. It is to monitor transfusion exposure, follow ferritin trends, evaluate organ function, use MRI when appropriate, and discuss whether chelation offers more benefit than risk. For selected people with transfusion-dependent lower-risk MDS, iron chelation can reduce iron burden and may help prevent important complications. For others, medication toxicity, advanced disease, limited life expectancy, or existing organ dysfunction may outweigh the potential benefit.
In other words, iron management in MDS is less like flipping a switch and more like adjusting a control panel. The correct setting depends on the whole patientnot just the largest number printed in bold on the laboratory report.
Experiences Related to Iron Overload in MDS
The following scenarios are educational composites based on commonly reported patient and caregiver experiences. They do not describe specific individuals.
The transfusion that helps today and complicates tomorrow
A person with lower-risk MDS may begin with occasional transfusionsperhaps one before a family trip or after fatigue becomes difficult to manage. The improvement can feel dramatic. Breathing becomes easier, the grocery store seems smaller, and the afternoon no longer requires a strategic alliance with the couch.
Over time, however, transfusions may become more frequent. Appointments that once appeared every few months begin showing up every four weeks, then every three. The immediate benefit remains obvious, while iron overload feels abstract because it usually causes no early symptoms. When the hematologist mentions that ferritin has climbed above 1,000, the patient may wonder why a treatment that makes them feel better is now creating another medical issue.
Understanding the trade-off helps. The transfusions are still doing their job. Iron monitoring simply addresses the accumulated cost of receiving them repeatedly.
Ferritin anxiety
Patients often become attached to laboratory numbers. A ferritin result may rise from 900 to 1,400 and trigger understandable alarm. At the next visit, it may fall slightly without any change in treatment. This can feel confusing or even suspicious.
The explanation is that ferritin is influenced by more than iron. A respiratory infection, inflammatory condition, liver irritation, or recent hospitalization may push it upward. Hematologists therefore look for a pattern rather than treating every fluctuation as an emergency.
A useful patient habit is to ask for the trend over six or twelve months. Seeing ferritin alongside transfusion dates, liver tests, and inflammatory events often makes the picture less mysterious. The goal is not to win a weekly battle against a laboratory value. It is to understand whether total iron burden is genuinely increasing.
Adjusting to chelation therapy
Starting an oral chelator may initially sound simple: take a tablet and remove excess iron. The lived experience can be more complicated. A patient may need additional blood tests, urine testing, dose changes, and discussions about diarrhea, nausea, appetite, kidney function, or other medications.
Some people tolerate deferasirox well after the dose and routine are adjusted. Others experience gastrointestinal symptoms that interfere with meals or daily activities. A patient may be tempted to skip doses silently, particularly when the drug treats a risk that cannot be felt. That silence makes it harder for the medical team to find a better schedule, lower dose, temporary interruption, or alternative approach.
Adherence is not a character test. A treatment plan that is technically effective but practically impossible needs revision. Patients benefit from reporting side effects early instead of waiting until frustration turns into complete discontinuation.
The caregiver’s hidden spreadsheet
Caregivers frequently become unofficial project managers. They track transfusion dates, laboratory values, medication refills, hydration, transportation, and symptomsall while trying not to make every dinner conversation sound like a hospital rounds presentation.
A simple transfusion log can reduce that burden. Useful columns include the date, number of units, pretransfusion hemoglobin, ferritin result, chelator dose, and major side effects. Bringing this record to appointments can reveal patterns that are difficult to reconstruct from memory.
The emotional side matters too. Iron overload adds another layer to an already complicated disease. Patients may feel frustrated that supportive care creates a second problem, while caregivers may worry about heart or liver damage years in advance. Clear explanations from the treatment team can transform those fears into manageable questions: How much iron is present? Is it affecting organs? Is treatment safe? What is the next checkpoint?
The value of an individualized plan
Two people with the same ferritin level may receive different recommendations. One may be a candidate for long-term chelation because the MDS is lower risk, transfusions are expected to continue, and kidney and liver function are strong. Another may be monitored without chelation because treatment toxicity would probably exceed the expected benefit.
This variation can be frustrating when patients compare stories in support groups. One person may say chelation improved their blood counts, while another stopped because of kidney changes. Both experiences can be valid without establishing a universal rule.
The most useful experience-based lesson is therefore not that everyone should start chelation at the same number. It is that transfusion burden should be tracked early, ferritin should be interpreted in context, side effects should be reported honestly, and treatment decisions should be revisited as MDS and overall health change.
Medical note: This article is for general education and does not replace individualized advice from a hematologist. Patients should not start, stop, or change iron chelation therapy, supplements, or transfusion schedules without medical guidance.
